Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone with/without Bortezomib in the Treatment of Newly Diagnosed Non-Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years). IFM2020-05/Benefit

Autor: Bobin, Arthur *, Lambert, Jerome *, Perrot, Aurore *, Manier, Salomon, Montes, Lydia *, Jaccard, Arnaud *, Karlin, Lionel *, Godmer, Pascal *, Caillot, Denis *, Hulin, Cyrille *, Chalopin, Thomas *, Roul, Christophe *, Mariette, Clara *, Rigaudeau, Sophie *, Dingremont, Claire *, Santagostino, Alberto *, Dib, Mamoun *, Macro, Margaret *, Tiab, Mourad *, Laribi, Kamel *, Bourgeois-Petit, Emmanuelle *, Calmettes, Claire *, Orsini, Frederique *, Tabrizi, Reza *, Vincent, Laure *, Mohty, Mohamad, Touzeau, Cyrille *, Corre, Jill *, Moreau, Philippe *, Facon, Thierry *, Avet Loiseau, Herve, Leleu, Xavier
Zdroj: In Blood 15 November 2022 140 Supplement 1:4423-4425
Databáze: ScienceDirect